14.39
price down icon0.69%   -0.10
pre-market  Pre-market:  14.16   -0.23   -1.60%
loading
Biohaven Ltd stock is traded at $14.39, with a volume of 2.14M. It is down -0.69% in the last 24 hours and down -7.46% over the past month. Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$14.49
Open:
$14.63
24h Volume:
2.14M
Relative Volume:
0.76
Market Cap:
$2.17B
Revenue:
-
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.5379
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
+5.58%
1M Performance:
-7.46%
6M Performance:
+25.13%
1Y Performance:
+6.83%
1-Day Range:
Value
$14.18
$14.75
1-Week Range:
Value
$13.61
$14.93
52-Week Range:
Value
$7.48
$18.57

Biohaven Ltd Stock (BHVN) Company Profile

Name
Name
Biohaven Ltd
Name
Phone
203-404-0410
Name
Address
215 CHURCH STREET, NEW HAVEN, CT
Name
Employee
274
Name
Twitter
@biohavenpharma
Name
Next Earnings Date
2026-08-10
Name
Latest SEC Filings
Name
BHVN's Discussions on Twitter

Compare BHVN vs VRTX, REGN, ARGX, RVMD, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
BHVN icon
BHVN
Biohaven Ltd
14.39 2.19B 0 -647.68M -594.49M -5.67
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
525.73 134.25B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
797.99 82.06B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
876.00 54.10B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
205.26 44.06B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
359.05 40.64B 5.76B 514.49M 1.10B 4.4813

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-13-26 Initiated Canaccord Genuity Buy
Feb-06-26 Initiated Goldman Buy
Jan-21-26 Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-03-25 Downgrade H.C. Wainwright Buy → Neutral
Nov-26-25 Downgrade UBS Buy → Neutral
Nov-06-25 Downgrade Bernstein Outperform → Mkt Perform
Nov-05-25 Downgrade BofA Securities Buy → Neutral
Sep-17-25 Initiated Citigroup Buy
Sep-03-25 Initiated Raymond James Strong Buy
May-19-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-11-25 Initiated Deutsche Bank Buy
Sep-16-24 Initiated Jefferies Buy
Sep-04-24 Initiated Bernstein Outperform
Jul-24-24 Initiated Morgan Stanley Overweight
Feb-16-24 Initiated RBC Capital Mkts Outperform
Feb-06-24 Initiated UBS Buy
Dec-22-23 Initiated H.C. Wainwright Buy
Dec-08-23 Initiated Robert W. Baird Outperform
Jan-24-23 Initiated SVB Securities Outperform
Jan-04-23 Initiated JP Morgan Overweight
Dec-02-22 Initiated BTIG Research Buy
Oct-26-22 Upgrade Cantor Fitzgerald Neutral → Overweight
Oct-12-22 Initiated Piper Sandler Overweight
Aug-19-22 Downgrade Piper Sandler Overweight → Neutral
Aug-08-22 Downgrade Wedbush Outperform → Neutral
May-11-22 Downgrade SVB Leerink Outperform → Mkt Perform
Oct-19-21 Resumed Morgan Stanley Equal-Weight
Aug-10-21 Downgrade UBS Buy → Neutral
Aug-03-21 Reiterated Canaccord Genuity Buy
Mar-11-21 Initiated UBS Buy
Dec-15-20 Initiated H.C. Wainwright Buy
Apr-17-20 Initiated Cowen Outperform
Feb-10-20 Downgrade Oppenheimer Outperform → Perform
Feb-06-20 Initiated Mizuho Buy
Nov-22-19 Initiated Wedbush Outperform
Jun-25-19 Reiterated Canaccord Genuity Buy
May-06-19 Initiated Goldman Buy
Apr-09-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-04-19 Reiterated Needham Buy
Jul-03-18 Reiterated Needham Buy
Jul-02-18 Reiterated Needham Buy
Apr-05-18 Downgrade Barclays Overweight → Equal Weight
Feb-22-18 Reiterated Canaccord Genuity Buy
Dec-15-17 Initiated Canaccord Genuity Buy
Oct-03-17 Reiterated Needham Buy
View All

Biohaven Ltd Stock (BHVN) Latest News

pulisher
Aug 11, 2026

Biohaven 2Q Loss/Shr 91c >BHVN - Moomoo

Aug 11, 2026
pulisher
Aug 11, 2026

Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada

Aug 11, 2026
pulisher
Aug 11, 2026

Biohaven Supported by Multiple Pipeline Catalysts, Cash Runway Into 2027, RBC Says - Moomoo

Aug 11, 2026
pulisher
Aug 11, 2026

Biohaven Pharma stock price target raised to $23 by RBC Capital - Investing.com South Africa

Aug 11, 2026
pulisher
Aug 11, 2026

Biohaven Ltd. (BHVN) Stock Analysis: Exploring The 57.73% Potential Upside For Investors - DirectorsTalk Interviews

Aug 11, 2026
pulisher
Aug 10, 2026

Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance Australia

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven (NYSE:BHVN) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS - MarketBeat

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven Ltd. Announces Q2 2026 Financial Results Highlighting Reduced Losses and R&D Spending - Kalkine Media

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven reports Q2 2026 net loss of $137.3M, cash and marketable securities $267.9M - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven (NYSE: BHVN) reports $267.8M H1 2026 loss and $267.9M in liquidity - Stock Titan

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven Ltd. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 10, 2026
pulisher
Aug 10, 2026

Biohaven Ltd. $BHVN Shares Purchased by The Manufacturers Life Insurance Company - MarketBeat

Aug 10, 2026
pulisher
Aug 09, 2026

Biohaven earnings set to show cash burn ahead of epilepsy data - Investing.com UK

Aug 09, 2026
pulisher
Aug 09, 2026

Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Aug 09, 2026
pulisher
Aug 09, 2026

Understanding Momentum Shifts in (BHVN) - Stock Traders Daily

Aug 09, 2026
pulisher
Aug 07, 2026

Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade

Aug 07, 2026
pulisher
Aug 07, 2026

Biohaven (BHVN) Institutional Ownership 2026 - marketbeat.com

Aug 07, 2026
pulisher
Aug 06, 2026

Biohaven (BHVN) Adds AI Expertise To Its Board, Is The Valuation Gap Too Wide? - simplywall.st

Aug 06, 2026
pulisher
Aug 06, 2026

Biohaven Appoints Technology Investor John Yetimoglu to Board of Directors - Morningstar

Aug 06, 2026
pulisher
Aug 06, 2026

Biohaven Ltd. Announces Appointment of John Yetimoglu to Board of Directors, Effective August 6, 2026 - marketscreener.com

Aug 06, 2026
pulisher
Aug 06, 2026

Biohaven appoints AI and tech investment expert John Yetimoglu to its Board to boost AI-driven drug development. - Pluang

Aug 06, 2026
pulisher
Aug 04, 2026

Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 71.53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Aug 04, 2026
pulisher
Aug 03, 2026

Biohaven (BHVN) Expected to Release Quarterly Earnings on Monday - MarketBeat

Aug 03, 2026
pulisher
Aug 03, 2026

Defilade Capital Management L.P. Buys Shares of 315,944 Biohaven Ltd. $BHVN - MarketBeat

Aug 03, 2026
pulisher
Jul 30, 2026

Biohaven Insiders Added US$33.1m Of Stock To Their Holdings - Moomoo

Jul 30, 2026
pulisher
Jul 28, 2026

Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 58% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Jul 28, 2026
pulisher
Jul 27, 2026

How Biohaven’s (BHVN) Trade Secret Verdict Shapes Its Intellectual Property Defense Strategy - simplywall.st

Jul 27, 2026
pulisher
Jul 27, 2026

Federal jury awards Yale University, Biohaven $4M in trade secret suit - Westfair Communications

Jul 27, 2026
pulisher
Jul 27, 2026

Yale, Biohaven Win $4M In Biotech Trade Secret Trial - Law360

Jul 27, 2026
pulisher
Jul 27, 2026

Why is Biohaven Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

Yale, Biohaven Win $4 Million Verdict Over Drug-Development Tech - Bloomberg Law News

Jul 27, 2026
pulisher
Jul 27, 2026

Federal jury awards Yale, Biohaven $4M in lawsuit over trade secrets - Hartford Business Journal

Jul 27, 2026
pulisher
Jul 27, 2026

Biohaven and Yale win $4M verdict in trade secret case - Investing.com Nigeria

Jul 27, 2026
pulisher
Jul 27, 2026

Federal Jury Finds Avilar Therapeutics and RA Capital Willfully and Maliciously Misappropriated Trade Secret Developed at Yale, Awards Biohaven and Yale University $4 Million - tradingview.com

Jul 27, 2026
pulisher
Jul 27, 2026

Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Biohaven Ltd (BHVN) Institutional Confidence - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

BHVN|Biohaven Ltd|Price:14.320|Chg%:-0.320 - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

BHVN|Biohaven Ltd|Price:14.563|Chg%:+0.243 - TradingKey

Jul 26, 2026
pulisher
Jul 25, 2026

Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Biohaven Ltd. Revenue Breakdown – NYSE:BHVN - TradingView

Jul 25, 2026
pulisher
Jul 21, 2026

Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 53% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

Jul 21, 2026
pulisher
Jul 20, 2026

Biohaven Pharmaceutical Holding Company Ltd (BHVN) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits

Jul 20, 2026
pulisher
Jul 20, 2026

Biohaven to Present New Clinical Data at ESMO Congress on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload - Finansavisen

Jul 20, 2026
pulisher
Jul 18, 2026

How Biohaven’s (BHVN) R&D Leadership Shuffle Will Impact Investors - simplywall.st

Jul 18, 2026
pulisher
Jul 17, 2026

Biohaven Ltd. (NYSE: BHVN) legal chief discloses holdings - Stock Titan

Jul 17, 2026
pulisher
Jul 17, 2026

Lobbying Update: $120,000 of BIOHAVEN LTD. lobbying was just disclosed - Quiver Quantitative

Jul 17, 2026
pulisher
Jul 17, 2026

Biohaven files Form 3 for Chief Legal Officer Warren Karl Volles - Bitget

Jul 17, 2026
pulisher
Jul 17, 2026

Price to book forward of Biohaven Ltd. – NYSE:BHVN - TradingView

Jul 17, 2026

Biohaven Ltd Stock (BHVN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$63.67
price up icon 5.12%
$36.16
price up icon 2.58%
$59.22
price up icon 2.47%
$132.28
price down icon 0.22%
$223.95
price up icon 1.24%
ONC ONC
$359.05
price down icon 0.06%
Cap:     |  Volume (24h):